menu
    • menu

    Company profile for Equillium

    NEW Drugs in Dev: 7
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our initial product candidate, EQ001, is a clinical stage first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus and multiple sclerosis. We believe EQ001 may have broad therapeutic utility and our current ...
    Our initial product candidate, EQ001, is a clinical stage first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus and multiple sclerosis. We believe EQ001 may have broad therapeutic utility and our current pipeline is focused on developing EQ001 as a best-in-class treatment for multiple severe immuno-inflammatory disorders.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    EquilliumUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    601 Gateway Blvd., Suite 1020 South San Francisco, CA 94080
    Telephone
    Telephone
    858 412 5302
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.equilliumbio.com/home/default.aspx
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BePharma

    Not Confirmed

    envelop Contact Supplier

    BePharma

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Equillium To Join Leerink Partners Global Healthcare Conference
    Equillium To Join Leerink Partners Global Healthcare Conference

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244592/0/en/Equillium-to-Participate-in-the-Leerink-Partners-2026-Global-Healthcare-Conference.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share
    Equillium Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
    Equillium Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)

    02 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/02/3230599/0/en/Equillium-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    02 Feb 2026
    Share Share
    Equillium To Participate In Upcoming Investor Conferences
    Equillium To Participate In Upcoming Investor Conferences

    20 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/20/3192430/0/en/Equillium-to-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    20 Nov 2025
    Share Share
    Equillium Updates On Q3 2025 Finances And Operations
    Equillium Updates On Q3 2025 Finances And Operations

    13 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/13/3187833/0/en/Equillium-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Operational-Update.html

    GLOBENEWSWIRE
    13 Nov 2025
    Share Share
    Equillium To Participate In Upcoming Investor Conferences
    Equillium To Participate In Upcoming Investor Conferences

    04 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/04/3180352/0/en/Equillium-to-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    04 Nov 2025
    Share Share
    Equillium Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
    Equillium Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179807/0/en/Equillium-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search